Grant Award Details
- To establish feasibility of human a iPSC-derived medial ganglionic eminence progenitor cell candidate for the treatment of traumatic brain injury that is ready for translational stage activities.
Grant Application Details
- Optimization of a human interneuron cell therapy for traumatic brain injury
A cell therapy product comprised of inhibitory neurons that can migrate, integrate and restore neurologic function after traumatic brain injury.
Traumatic brain injury
Major Proposed Activities
- Examine the most effective dose and safety profile of human iPSC-derived MGE cells grafted into rodent hippocampus.
- Determine whether human iPSC-derived MGE cells mature into appropriate cortical interneurons in the traumatically injured brain
- Evaluate the effect of human GABA neurons on synaptic activity in the injured brain
- Evaluate the therapeutic potential of human-derived interneurons
Nearly 6 million Americans - including 700,000 Californians - live with permanent physical or mental health problems resulting from a traumatic brain injury, but there are no treatments. We propose studies to create a cell therapy product that is capable of restoring neurologic function to these patients.